MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 50.85.
| Share Price | ₹2,371.8 | Jun 10,2026 |
| Market Cap | ₹97,953.3 Cr | |
| Earnings-TTM | ₹1,926.4 Cr | TTM-Consolidated Results |
| Price/Earnings | 50.85x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹97,953.3 Cr] as on Jun 10,2026
(/) Earnings [ ₹1,926.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 50.85x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 50.85 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.67x.
- MANKIND PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 1,926.41 | 50.85 | 97,953.3 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 37.08 | 428,785.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 68.63 | 176,242.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 70.65 | 151,058.0 |
| CIPLA LTD | 3,869.79 | 28.73 | 111,180.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 25.61 | 106,149.0 |
| LUPIN LTD | 5,355.47 | 19.20 | 102,818.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 21.98 | 110,474.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 23.89 | 83,654.2 |
| LAURUS LABS LTD | 889.85 | 84.09 | 74,827.3 |
| BIOCON LTD | 368.80 | 181.98 | 67,113.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 19.20x |
| Max industry PE | 181.98x |
| Median industry PE | 37.08x |
| Average industry PE | 55.70x |
You may also like the below Video Courses